SCHEMBL24001

SCHEMBL24001

COc1ccc(OC)c(C(=O)Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.66
HTT P42858 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
POLB P06746 2/20 0.61
ALDH1A1 P00352 2/20 0.58
ABCG2 Q9UNQ0 1/20 0.57
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PDE4A P27815 1/20 0.53
PDE4B Q07343 1/20 0.53
PDE4C Q08493 1/20 0.53
PDE4D Q08499 1/20 0.53
RAB9A P51151 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
HSD17B10 Q99714 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8830902 0.86 MAPT (0.54) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL220681 0.85 NPC1 (0.64) MAPTHTTALDH1A1ABCG2MEN1
SCHEMBL23292541 0.84 MAPT (0.54) MAPTHTTNPSR1POLBMEN1
SCHEMBL12228747 0.84 MAPT (0.82) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL11197823 0.84 NPC1 (0.55) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL2580242 0.83 MAPT (0.47) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL885028 0.82 MAPT (0.68) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL11365109 0.82 ACHE (0.54) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL29581343 0.82 MAPT (0.68) MAPTHTTNPSR1POLBALDH1A1
SCHEMBL503802 0.82 POLB (0.70) MAPTHTTNPSR1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9870909-B2 Compositions and methods for mass spectometry MSTM, LLC 2018-01-16 US claimed
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME KULEON LLC (US) 2026-04-02 US disclosed
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS KULEON LLC (US) 2025-11-06 US disclosed
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same Kuleon, LLC (US) 2025-10-14 US disclosed
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME KULEON LLC (US) 2025-09-11 US disclosed
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression Kuleon, LLC (US) 2025-07-01 US disclosed
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators Kuleon, LLC (US) 2025-04-15 US disclosed
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION Kuleon, LLC (US) 2025-03-20 US disclosed
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators Kuleon, LLC (US) 2025-01-07 US disclosed
US-20240343690-A1 Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators KULEON LLC (US) 2024-10-17 US disclosed
EP-0761669-A2 Pentacyclic compounds, intermediates, processes, compositions, and methods ELI LILLY AND COMPANY (US) 1997-03-12 EP disclosed
US-5430062-A Combretastatin analogues; inhibition of tubulin polymerization and colchicine binding; antitumor,-mitotic and -neoplastic agents RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-07-04 US disclosed
WO-1993023357-A1 STILBENE DERIVATIVES AS ANTICANCER AGENTS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-11-25 WO disclosed
US-5153226-A Administering as anticholesterol agents, for atherosclerosis WARNER-LAMBERT COMPANY (US) 1992-10-06 US disclosed
EP-0415413-A1 Acat inhibitors WARNER-LAMBERT COMPANY (US) 1991-03-06 EP disclosed
EP-0059988-B1 PHOTOPOLYMERISABLE COMPOSITION, ESPECIALLY FOR THE PREPARATION OF PRINTING PLATES AND RELIEF FORMS BASF Aktiengesellschaft (DE) 1984-07-11 EP disclosed
US-4385109-A ACYL PHOSPHINE OXIDE PHOTOINITIATOR BASF AKTIENGESELLSCHAFT (DE) 1983-05-24 US disclosed
EP-0059988-A1 Photopolymerisable composition, especially for the preparation of printing plates and relief forms BASF Aktiengesellschaft (DE) 1982-09-15 EP disclosed
US-4292152-A UNSATURATED MONOMER, BINDER BASF AKTIENGESELLSCHAFT (DE) 1981-09-29 US disclosed
US-4069224-A N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS THE UPJOHN COMPANY (US) 1978-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME HTR2C, HTR7, HTR6 MAPT 3403/4885HTT 412/4885NPSR1 58/4885
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME HTR7, HTR2C, HTR1A MAPT 1778/4885HTT 310/4885NPSR1 53/4885
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same HTR7, HTR2C, HTR1A MAPT 1778/4885HTT 310/4885NPSR1 53/4885
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators HTR2A, HTR2C, HTR1A MAPT 2422/4885HTT 190/4885NPSR1 31/4885
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators HTR2C, HTR2A, HTR3B MAPT 3402/4885HTT 268/4885NPSR1 35/4885
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS HTR2A, HTR2C, HTR3A MAPT 2985/4885HTT 272/4885NPSR1 33/4885
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression HTR2A, HTR2C, HTR3A MAPT 3756/4885HTT 312/4885NPSR1 33/4885
US-20240343690-A1 Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators HTR2A, HTR2C, HTR1A MAPT 2422/4885HTT 190/4885NPSR1 31/4885
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION HTR2A, HTR2C, HTR3A MAPT 3756/4885HTT 312/4885NPSR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.